Meet us at BIO Europe Spring 2021

Meet Sciomics at Bio Europe Spring - Focus: COVDI-19 Disease Severity Biomarkers

Poster presentation at the AD/PD 2021

Sciomics presents a poster on biomarkers in Neurodegenerative Diseases at the ADPD202

Protein Profiling Platform - Quality Assurance

High quality standards are essential for robust and reliable Biomarker Discovery and Verification as well as for the discovery of new Drug Targets. During the last 10 years a stringent quality assurance workflow has been established for our Antibody Array Platform in order to conduct immuno-based biomedical discovery studies with excellent standards in terms of reproducibility and platform stability. The automated assay workflow further improves the performance of our service. 

 

Biomarker Discovery Phase - scioDiscover Platform

  • Stringent antigen design for maximised specificity of the resulting antibodies
  • Antibodies are antigen affinity-purified
  • Targets identified through transcriptional studies and expert input
  • Stringent QC management
  • Features:  
    • cross-species activity (human and mouse for high versatility)
    • detection of several protein isoforms
    • cost-efficiency through high content

  

Verification Phase - Custom Array Platform

  • Stringent antigen design for maximised specificity of the resulting antibodies
  • Antibodies are antigen affinity-purified
  • In-house QC on Western Blot (different cell lines or tissues) and optional ELISA-based tests
  • In-house QC on large-scale protein arrays (> 9.000 human proteins)
  • In-depth validation of array performance
  • Definition of biomarker signature with highest accuracy
  • Selection of appropriate binders / sandwich pairs
  • Features:  
    • specifically designed antibodies for further use in diagnostic assays
    • fully renewable antibody formats
    • in-depth quality controlled (WB, ELISA)
    • comprehensive cross-reactivity profile (large-scale protein arrays)

 

Orthogonal Biomarker Validation

Verified Candidates can be further validated by orthogonal methods according to customer’s requirements

  • Western Blotting ( WB )
  • ELISA
  • Immuno-Precipitation ( IP )
  • Mass spectrometry ( MS )
  • Biacore

 

Overview
Scio-Discover
    Biomarker
Discovery
    Custom Microarrays
for Biomarker Verification
    Contact
us

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…
Read more
scioDiscover - Protein Profiling on expression level

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell surface marker and Cytokine profiling

scioCD - Cell surface marker and Cytokine profiling

  Characterise a certain cell type?   Cell composition in a certain tissue sample?   In-depth profiling of CD-marker expression?   Increase your throughput at high sensitivity levels? You aim…
scioUbi

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay.   Features Screen…
scioCyto : Cytokine profiling

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD  platform to profile CD8+SLAMF7+ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8+SLAMF7+ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8+SLAMF7+ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8+SLAMF7+ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

 

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD  platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

 

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho  platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

 

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

 

New article | Protection from ischemia reperfusion injury-induced inflammation and fibrosis in C5aR2-deficient mice

| June 2018 | Complement component 5a receptor 2 (C5AR2) deficient mice are protected from inflammation and fibrosis in response to ischemia reperfusion injury. Our scioPhospho platform supported scientists at the Medical School Hannover to elucidate the underlying mechanism. The data were recently published in Kidney International.

 

Testimonials

"The quality of the data we have obtained is exceptional."

 

Prof. Claudio Mauro
Birmingham University, Institute of Inflammation and Ageing, Birmingham, UK

"We have performed an acetylation array on primary T lymphocytes with Sciomics. The quality of the data we have obtained is exceptional. They have a model of collaboration with the team conducting the experiment. This means they generate the data and assist with further analyses of the data. The screening has opened up several exciting ways forward for us."

Product: scioAcetyl protein and protein acetylation profiling service (under co-development with selected partners)

 

Tweets